Quantum-Si incorporated (QSI) Stock Price & Analysis
Quantum-Si incorporated (QSI) closed at USD 1.72 on Wednesday, October 28, 2026, up 4.24% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.65; the Oct 28, 2026 session ranged USD 1.59–1.73 on volume of 9,949,577 shares. Market capitalization is $376.48M, with a 52-week range of USD 0.69–2.23 (NGM). Source: Nexqual, retrieved October 29, 2026 at 06:08 UTC.
Also available as compact Markdown for AI agents: nexqual.com/QSI.md
Key facts (QSI)
- Last four reported quarters (through Jun 30, 2026): revenue $1.6M, net income -$98.5M (-6138.3% margin), free cash flow -$93.7M (SEC filings).
- Insider open-market sales, last ~7 months: 9 Form 4 filings, $353K; 9 not under a Rule 10b5-1 plan ($353K); 0 by opportunistic insiders, 2 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.33 on a 1–5 scale) (3 analysts), mean target USD 2.28 (range 1–3.95).
- Total return with dividends: 1Y -19.6% vs S&P 500 +13.6%; 5Y -78.7% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.12, revenue estimate $268K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (QSI)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0K | $0K | $1.1M | $3.1M | $2.4M | $1.6M |
| Gross profit | $0K | $0K | $488K | $1.6M | $1.2M | — |
| Operating income | -$96.9M | -$124M | -$111M | -$109M | -$116M | -$111M |
| Net income | -$95.0M | -$132M | -$96.0M | -$101M | -$101M | -$98.5M |
| EPS (diluted) | -$1.19 | -$0.95 | -$0.68 | -$0.71 | -$0.51 | — |
| Free cash flow | -$72.6M | -$101M | -$98.5M | -$92.4M | -$97.2M | -$93.7M |
| Gross margin | — | — | 45.1% | 52.3% | 47.3% | — |
| Operating margin | — | — | -10274.6% | -3550.6% | -4766.0% | -6887.8% |
| Net margin | — | — | -8868.8% | -3303.0% | -4160.1% | -6138.3% |
| Revenue growth | — | — | — | +182.6% | -20.3% | — |
| Cash + short-term investments | $471M | — | — | $210M | $216M | — |
| Total debt | $0K | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (QSI)
P/S 234.6x · P/B 2.1x · FCF yield -24.89% · Earnings yield -26.17%
Insider sales (SEC Form 4, open-market, last ~7 months) (QSI)
0 of 9 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-21…2026-09-22 | Hawkins Jeffrey Alan | President & CEO | 29,852 | $23K | 0.8% | No | Too little history (no open-market trades in 2023) |
| 2026-09-21…2026-09-22 | Keyes Jeffry R. | Chief Financial Officer | 7,665 | $6K | 0.4% | No | Too little history (no open-market trades in 2023) |
| 2026-09-21…2026-09-22 | Lapointe Christian | GC & Corp. Secretary | 14,516 | $11K | 1.2% | No | Routine (traded in Mar each year 2023–2025; this trade is outside those months) |
| 2026-06-22…2026-06-23 | Lapointe Christian | GC & Corp. Secretary | 15,588 | $14K | 1.3% | No | Routine (traded in Mar each year 2023–2025; this trade is outside those months) |
| 2026-06-22…2026-06-23 | Keyes Jeffry R. | Chief Financial Officer | 8,233 | $8K | 0.5% | No | Too little history (no open-market trades in 2023) |
| 2026-06-22…2026-06-23 | Vieceli John S. | Chief Product Officer | 30,223 | $28K | 2.6% | No | Too little history (no open-market trades in 2023) |
| 2026-06-22…2026-06-23 | Hawkins Jeffrey Alan | President & CEO | 22,621 | $21K | 0.6% | No | Too little history (no open-market trades in 2023) |
| 2026-04-20…2026-04-21 | Keyes Jeffry R. | Chief Financial Officer | 74,763 | $75K | 4.1% | No | Too little history (no open-market trades in 2023) |
| 2026-04-20…2026-04-21 | Hawkins Jeffrey Alan | President & CEO | 167,424 | $168K | 4.3% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (QSI)
Consensus Buy (mean 2.33 on a 1–5 scale), 3 analysts; mean target USD 2.28 (low 1, high 3.95).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | HC Wainwright & Co. | Reiterated | Buy | $4 |
Total return (dividends reinvested) (QSI)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -19.6% | -78.7% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -19.7% | -26.5% |
| Volatility (annualized) | 95.8% | 110.6% |
| Max drawdown | -67.3% (Oct 2025→Jul 2026) | -91.3% (Nov 2021→Jul 2026) |
QSI major shareholder filing: Schedule 13D/A, Aug 28, 2026
ROTHBERG JONATHAN M, ROTHBERG JONATHAN M., 23rd Century Capital LLC filed a Schedule 13D/A with the SEC on Aug 28, 2026, reporting up to 100.00% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:
In connection with estate planning, entities owned by trusts created for the benefit of Dr. Jonathan Rothberg's children have entered into a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Plan"), a copy of which is attached hereto as Exhibit 6. Pursuant to the Plan, sales of up to 8,947,746 shares of Class A common stock may be effected during the plan sales period beginning following the cooling-off period contained in Rule 10b5-1(c) on January 15, 2027 and ending on January 15, 2028 in accordance with the terms and conditions of the Plan. The sale of shares of Class A common stock under the Plan is subject to minimum price parameters included in the Plan, and there is no assurance that any shares of Class A common stock will be sold under the Plan.
Source: SEC EDGAR, Schedule 13D/A filed Aug 28, 2026. Quoted word for word; Nexqual adds no interpretation.
QSI earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 13, 2026 | Quarter ended Jun 30, 2026 | −$0.10 | −$0.10 | In line | -11.6% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | −$0.09 | −$0.10 | Beat +10.0% | -11.9% |
| Mar 3, 2026 | Quarter ended Dec 31, 2025 | −$0.08 | −$0.13 | Beat +38.5% | -2.5% |
| Nov 5, 2025 | Quarter ended Sep 30, 2025 | −$0.09 | −$0.12 | Beat +25.0% | -10.3% |
| Aug 5, 2025 | — | — | — | — | -4.9% |
| May 15, 2025 | — | — | — | — | -2.6% |
| Mar 3, 2025 | — | — | — | — | +0.0% |
| Nov 12, 2024 | — | — | — | — | -20.9% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
QSI recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 15, 2026 | 8-K | Other material event “As previously disclosed, on July 23, 2026, Quantum-Si Incorporated (the "Company") received written notice (the "Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, because the closing bid price for the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"), had fallen below $1.00 per share for 30 consecutive business days, the Company no longer met the minimum bid price requirement for continued inclusion…” |
| Oct 8, 2026 | 8-K | Regulation FD disclosure |
| Sep 29, 2026 | 8-K | Regulation FD disclosure |
| Aug 28, 2026 | Schedule 13D/A | ROTHBERG JONATHAN M, ROTHBERG JONATHAN M.: 100.0% of shares, 5%+ holder that may seek to influence the company (amended) “In connection with estate planning, entities owned by trusts created for the benefit of Dr. Jonathan Rothberg's children have entered into a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Plan"), a copy of which is attached…” |
| Aug 13, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 13, 2026 | 8-K | Quarterly results |
| Jul 29, 2026 | Schedule 13G/A | BlackRock, Inc.: 2.3% of shares, passive 5%+ holder (amended) |
| Jul 24, 2026 | 8-K | Delisting notice or listing-rule failure “On July 23, 2026, Quantum-Si Incorporated (the "Company") received written notice (the "Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, because the closing bid price for the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Global…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
QSI revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $314,000 | 91.3% | -43.7% |
| Service | $30,000 | 8.7% | -9.1% |
| Total revenue | $344,000 | 100% | — |
QSI revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| International Sales | $262,000 | 76.2% | -39.8% |
| Domestic Sales | $82,000 | 23.8% | -47.4% |
| Total revenue | $344,000 | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
QSI suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | Thermo Fisher (TMO) | “We also may compete with a number of emerging growth companies that have developed, or are developing, proteomic products and solutions, such as Nautilus Biotechnology, Olink Proteomics (acquired by Thermo Fisher Scientific), Quanterix, Seer and SomaLogic (acquired by Illumina, Inc.).” |
Quoted from the company's 10-K filed Mar 3, 2026.
QSI company outlook (results filed Aug 13, 2026)
- “For the full year 2026 , the Company reiterated the following financial guidance, as initially issued on March 3, 2026: Revenue: Approximately $1.0 million Adjusted total operating expenses: $98.0 million or less Total cash usage: $93.0 million or less The Company continues to view 2026 as a transition year ahead of the anticipated Proteus launch.”
- “The updated anticipated launch timing of Q2 2027 is intended to allow the Company to complete additional integrated instrument design and testing work, advance verification and validation activities, and further prepare for manufacturing and commercial launch.”
- “The Company expects 2026 revenue to continue to reflect the transition from Platinum to Proteus, including customer purchasing behavior, installed-base consumable activity, and customer planning for the anticipated new platform.”
- “The Company plans to manage spending against the revised launch timeline while maintaining the resources needed to advance Proteus toward commercialization. 2 Total cash usage is expected to include Proteus development, selected inventory investments, and commercial readiness activities supporting the updated Q2 2027 anticipated launch timing.”
Quoted word-for-word from the SEC 8-K results press release.
QSI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.12 | $-0.11 | −$0.01 | $268,330 | 1 |
| Next quarter (ends Dec 2026) | $-0.10 | $-0.11 | +$0.01 | $242,330 | 1 |
| Current fiscal year (ends Dec 2026) | $-0.40 | $-0.40 | $0.00 | $1.1M | 1 |
| Next fiscal year (ends Dec 2027) | $-0.35 | $-0.36 | +$0.01 | $5.8M | 1 |
QSI options: expected move
Options price a move of about ±50.6% (±$0.85) by Nov 6, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±8.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 2 | 221.2% | ±16.4% |
| Nov 6, 2026 | 9 | 193.4% | ±50.6% |
| Nov 13, 2026 | 16 | 198.5% | ±46.1% |
| Nov 20, 2026 | 23 | 218.4% | ±41.7% |
| Nov 27, 2026 | 30 | 255.3% | ±53.6% |
| Dec 18, 2026 | 51 | 151.7% | ±77.4% |
| Jan 15, 2027 | 79 | 131.0% | ±46.1% |
| Apr 16, 2027 | 170 | 117.8% | ±59.5% |
30-day implied volatility 111.5% vs 170.6% realized over the last 30 trading days. Put/call ratio (volume) 0.09. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 06:08 UTC)
| Price | USD 1.72 |
|---|---|
| Change | ▲ 4.24% (up) |
| Previous Close | USD 1.65 |
| Open | USD 1.63 |
| Day Range | USD 1.59 – 1.73 |
| 52-Week Range | USD 0.69 – 2.23 |
| Volume | 9,949,577 shares |
| Market Cap | $376.48M |
| Exchange | NGM |
Technical Analysis (QSI)
Nexqual's technical model rates QSI "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 29, 2026 at 06:08 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 68.71 (neutral) |
| vs SMA50 | Above (USD 1.01) |
| MACD | 0.14 (positive) |
Analyst Ratings (QSI)
Wall Street analysts rate QSI "Buy" based on 3 analysts, with a mean price target of USD 2.28 (range USD 1–3.95), per Nexqual as of October 29, 2026 at 06:08 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 2.28 |
| High Target | USD 3.95 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (QSI)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.12 |
| Revenue Estimate | $268,330 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.1 vs est -0.1 ▲ beat |
| 2026-03-31 | USD -0.09 vs est -0.1 ▲ beat |
| 2025-12-31 | USD -0.08 vs est -0.13 ▲ beat |
| 2025-09-30 | USD -0.09 vs est -0.12 ▲ beat |
Source: Nexqual, October 29, 2026 at 06:08 UTC.
Financials & Fundamentals (QSI)
| Total Revenue | $1.60M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -41.80% |
| Gross Margin | +35.02% |
| Operating Margin | -7450.29% |
| Profit Margin | +0.00% |
| ROE | -49.11% |
| Debt / Equity | 0.02 |
| Current Ratio | 9.97 |
| Total Cash | $111.74M |
| Total Debt | $3.25M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$93.69M (-5837.3% of revenue) |
Source: Nexqual, October 29, 2026 at 06:08 UTC.
Financial Health Score (QSI)
Nexqual rates Quantum-Si incorporated's overall financial health "Weak" across five dimensions, as of October 29, 2026 at 06:08 UTC.
| Growth | Critical — Revenue -20% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $112M cash vs $3M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$94M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -55%, ROA -50.9% (last 4 quarters, SEC) |
Ownership (QSI)
| Insider Ownership | +10.45% |
|---|---|
| Institutional Ownership | +24.73% |
| Shares Outstanding | 198.95M |
| Float | 180.22M |
| Short % of Float | +7.41% |
Source: Nexqual, October 29, 2026 at 06:08 UTC.
Leadership (QSI)
Quantum-Si incorporated is led by Jeffrey Alan Hawkins, President, CEO & Director, per Nexqual as of October 29, 2026 at 06:08 UTC.
| President, CEO & Director | Jeffrey Alan Hawkins |
|---|---|
| Founder & Executive Director | Jonathan M. Rothberg |
| CFO & Treasurer | Jeffry R. Keyes C.P.A. |
Major Backers & Investors (QSI)
Notable institutional backers of Quantum-Si incorporated include ARK Invest, Sumitomo Mitsui Trust Group, Inc., Amova Asset Management Americas Inc, according to Nexqual as of October 29, 2026 at 06:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 3.6% |
| Sumitomo Mitsui Trust Group, Inc. | 1.95% |
| Amova Asset Management Americas Inc | 1.95% |
| Millennium Management | 1.57% |
| UBS Group AG | 1.29% |
| AQR Capital Management, LLC | 1.18% |
| Jane Street Group, LLC | 1.08% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.81% |
| BlackRock | 2.63% |
| Geode Capital | 1.12% |
Source: Nexqual, October 29, 2026 at 06:08 UTC.
From Quantum-Si incorporated's Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe our broad patent portfolio and continued rigorous patent protection strategy will help to allow us to focus on our key priorities of commercializing our platform, continuing to innovate with new technologies, and preventing fast-followers.
- We have developed a proprietary, universal, single-molecule detection platform that we are applying to proteomics to enable next-gen protein sequencing ("NGPS") to sequence proteins in a massively parallel fashion (rather than sequentially, one at a time), which can also be used for the study of nucleic acids.
- We believe we are the first company to have successfully commercialized a NGPS product.
- Protection of our intellectual property is a strategic priority for the business; we have taken, and will continue to take, steps to protect our current and future intellectual property and proprietary technology.
Partnerships
- In November 2024, we announced a North American distribution agreement with Avantor to distribute the Platinum Pro and related consumables.
- While traditional instruments like MS can cost up to $1,000,000 or more per new instrument, our Platinum device is currently priced at approximately $85,000.
Legal & Regulatory Risks (Item 1A, quoted)
- We may in the future register with the FDA as a specification developer and list some of our ancillary products with the FDA as Class I general purpose laboratory equipment, subjecting us to ongoing inspections by the FDA.
- Our research use only ("RUO") products could become subject to government regulation as medical devices by the U.S.
- Any legislative or administrative rule making or new federal oversight of LDTs, if and when finalized, may impact the sales of our products and how customers use our products, and may require us to change our business model in order to maintain compliance with these laws.
- Our reagents may be used by clinical laboratories to create Laboratory-Developed Tests ("LDTs"), which could, in the future, become subject to some form of FDA or other regulatory requirements, which could materially and adversely affect our business and results of operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INSP | Inspire Medical Systems, Inc. | USD 70.97 | ▼ 0.46% |
| ESTA | Establishment Labs Holdings Inc | USD 68.97 | ▲ 3.02% |
| BFLY | Butterfly Network, Inc. | USD 7.81 | ▲ 5.83% |
| UFPT | UFP Technologies, Inc. | USD 286 | ▼ 3% |
| TMDX | TransMedics Group, Inc. | USD 66.9 | ▼ 4.06% |
| ALMR | Alamar Biosciences, Inc. | USD 34.3 | ▲ 7.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:08 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt